FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic - CNBC
- FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic CNBC
- FTC Targets 'Junk' Patent Listings on Ozempic and Other Drugs The Wall Street Journal
- US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ABC News
- FTC Warns 'Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How Forbes
- Recon: FTC warns drugmakers over 'junk' Orange Book patents; FDA solicits public feedback on advisory committee reforms Regulatory Focus